This study is in progress, not accepting new patients

A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

a study on Multiple Sclerosis

Summary

for people ages 18–55 (full criteria)
at San Francisco, California and other locations
study started
estimated completion:

Description

Summary

This randomized, parallel group, double-blind, placebo controlled study will evaluate the efficacy and safety of ocrelizumab in participants with primary progressive multiple sclerosis. Eligible participants will be randomized 2 : 1 to receive either ocrelizumab or placebo. The blinded treatment period will be at least 120 weeks, followed by an Open Label Extension (OLE) treatment for participants in both groups who in the opinion of the investigator could benefit from further or newly initiated ocrelizumab treatment. Unless terminated early, all participants will continue their treatment with open-label ocrelizumab until the last participant who entered the OLE phase reaches 4 years of open-label ocrelizumab treatment.

Official Title

A Phase III, Multicentre, Randomized, Parallel-group, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

Keywords

Multiple Sclerosis, Primary Progressive Sclerosis Multiple Sclerosis Multiple Sclerosis, Chronic Progressive

Eligibility

You can join if…

Open to people ages 18–55

  • Diagnosis of primary progressive multiple sclerosis (according to revised McDonald criteria)
  • EDSS at screening from 3 to 6.5 points
  • Disease duration from onset of MS symptoms less than (<) 15 years if EDSS greater than(>) 5.0; <10 years if EDSS greater than or equal to (>/=) 5.0
  • Sexually active male and female participants of reproductive potential must use two methods of contraception throughout the study treatment phase and for 48 weeks after the last dose

You CAN'T join if...

  • History of relapsing remitting MS, secondary progressive, or progressive relapsing MS at screening
  • Inability to complete an MRI (contraindications for MRI)
  • Known presence of other neurologic disorders
  • Known active infection or history of or presence of recurrent or chronic infection
  • History of cancer, including solid tumors and hematological malignancies (except for basal cell, in situ squamous cell carcinomas of the skin and in situ carcinoma of the cervix that have been excised and resolved)
  • Previous treatment with B-cell targeted therapies (e.g. rituximab, ocrelizumab,atacicept, belimumab, or ofatumumab)
  • Any previous treatment with lymphocyte trafficking blockers, with alemtuzumab,anti-cluster of differentiation 4 (CD4), cladribine, cyclophosphamide, mitoxantrone,azathioprine, mycophenolate mofetil, cyclosporine, methotrexate, total body irradiation, or bone marrow transplantation
  • Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study

Locations

  • Univ of CA San Francisco; Department of Neurology
    San Francisco, California, 94143, United States
  • Sutter East Bay Medical Foundation
    Berkeley, California, 94705, United States
  • Univ of CA Davis Med Ctr; Neurology
    Sacramento, California, 95817, United States
  • MS Center of Southern California
    Newport Beach, California, 92663, United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Hoffmann-La Roche
ID
NCT01194570
Phase
Phase 3
Study Type
Interventional
Last Updated
December 20, 2017